{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089566","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.821274+00:00","generated_at":"2026-06-11T17:03:15.397829+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Milestone Pharma Q2 2023: cash $87.6M, NDA for etripamil due Oct 2023","bullets":["Cash, equivalents & short-term investments of $87.6M; runway into mid-2025.","NDA submission for etripamil nasal spray (PSVT) planned for October 2023.","Enrollment complete in Phase 2 ReVeRA trial (AFib-RVR); topline data Q4 2023.","Operating loss Q2 2023: $16.4M vs $16.8M in Q2 2022; R&D expense down to $8.6M.","Commercial expense rose to $3.4M in Q2 2023 from $2.2M a year earlier."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089566","json":"https://secwatch.observer/filing/0001104659-23-089566.json","markdown":"https://secwatch.observer/filing/0001104659-23-089566.md","text":"https://secwatch.observer/filing/0001104659-23-089566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923089566/0001104659-23-089566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923089566/tm2323072d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:03:15.397829+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b76303cb5a1b130febd2594629b0d4460ab4883","claim":"Milestone Pharmaceuticals Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 10, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023, which also provided a clinical and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923089566/0001104659-23-089566-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"518f52b2db7581b03afe0db03b19cbc64ce44326","claim":"Milestone Pharmaceuticals Inc. reported the six months ended June 30, 2023 results: net income operating loss was $31.9 million.","evidence_excerpt":"For the six months ended June 30, 2023, Milestone's operating loss was $31.9 million, compared to $30.9 million in the prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923089566/0001104659-23-089566-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Net income","value":"operating loss was $31.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}